Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 21;9(5):bio051680. doi: 10.1242/bio.051680

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Fig. 4. — FGF9 predicts poor survival in patients with CRC. (A) Immunohistochemical staining of FGF9, E-cadherin and Vimentin in paraffin-embedded human CRC tissues. Scale bars: 25 μm. (B) Immunohistochemical scores for FGF9 in normal colorectal mucosa and CRC tissues (n=37). (C) Immunohistochemical staining of FGF9 in well-, moderately and poorly differentiated CRC tissues. (D) Kaplan–Meier survival curves of CRC patients with low (n=15) and high (n=22) FGF9 expression. FGF9 was classified as high expression if the immunostaining score is more than four, otherwise classified as low expression. (E) Correlation test of immunostaining intensity between FGF9 and E-cadherin. (F) Correlation test of immunostaining intensity between FGF9 and Vimentin. *P<0.05, **P<0.01.